[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Tajima Y, Yamazaki K, Makino R, Nishino N, Masuda Y, Aoki S, Kato M, Morohara K, Kusano M: Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach. Br J Cancer; 2007 Feb 26;96(4):631-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differences in the histological findings, phenotypic marker expressions and genetic alterations between adenocarcinoma of the gastric cardia and distal stomach.
  • Adenocarcinoma of the gastric cardia (C-Ca) is possibly a specific subtype of gastric carcinoma.
  • The purpose of this study was to clarify the differences in the clinicopathological characteristics between C-Ca and adenocarcinoma of the distal stomach (D-Ca), and also the differences in the expressions of gastric and intestinal phenotypic markers and genetic alterations between the two.
  • The incidence of undifferentiated-type tumours was significantly higher in cases with advanced-stage C-Ca than in those with early-stage C-Ca (5 vs 36.5%, P=0.0076).
  • A significantly greater frequency of HGM expression in early-stage C-Ca and significantly lower frequency of MUC2 expression in advanced-stage C-Ca was observed as compared with the corresponding values in cases of D-Ca (78.9 vs 52.2%, P=0.0402 and 51.5 vs 84.6%, P=0.0247, respectively).
  • [MeSH-major] Adenocarcinoma / genetics. Adenocarcinoma / pathology. Biomarkers, Tumor / genetics. DNA, Neoplasm / genetics. Gene Expression Regulation, Neoplastic / genetics. Stomach Neoplasms / genetics. Stomach Neoplasms / pathology
  • [MeSH-minor] Aged. Cardia / pathology. DNA Mutational Analysis / methods. Disease Progression. Esophagus / pathology. Female. Humans. Male. Mutation. Neoplasm Invasiveness. Neoplasm Staging. Phenotype. Sensitivity and Specificity

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1994 Jun;129(6):609-14 [8204035.001]
  • [Cites] Gastroenterology. 1993 Feb;104(2):510-3 [8425693.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):723-34 [7657100.001]
  • [Cites] Gastroenterology. 1995 Sep;109(3):999-1001 [7657131.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):2015-21 [9164213.001]
  • [Cites] Int J Cancer. 1998 Mar 2;75(5):767-73 [9495247.001]
  • [Cites] Int J Cancer. 1999 Feb 19;84(1):28-32 [9988228.001]
  • [Cites] Cancer Res. 1999 Mar 1;59(5):1003-7 [10070955.001]
  • [Cites] Pathol Int. 1999 Jan;49(1):55-61 [10227725.001]
  • [Cites] Acta Pathol Microbiol Scand. 1965;64:31-49 [14320675.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):874-9 [15681533.001]
  • [Cites] J Cancer Res Clin Oncol. 2006 Jun;132(6):363-75 [16447040.001]
  • [Cites] World J Gastroenterol. 2006 Jun 28;12(24):3803-9 [16804962.001]
  • [Cites] J Natl Cancer Inst. 2006 Oct 18;98(20):1445-52 [17047193.001]
  • [Cites] Mutat Res. 2000 Jul 20;452(1):83-90 [10894894.001]
  • [Cites] Mod Pathol. 2000 Oct;13(10):1055-9 [11048797.001]
  • [Cites] Oncology. 2001;61(1):1-9 [11474241.001]
  • [Cites] Genes Chromosomes Cancer. 2001 Sep;32(1):50-8 [11477661.001]
  • [Cites] Gastroenterology. 2001 Sep;121(3):592-8 [11522743.001]
  • [Cites] Oncology. 2001;61(3):212-20 [11574777.001]
  • [Cites] Cancer. 2001 Oct 15;92(8):2228-33 [11596042.001]
  • [Cites] Int J Cancer. 2002 Feb 10;97(5):562-6 [11807778.001]
  • [Cites] Int J Cancer. 2002 May 20;99(3):336-43 [11992401.001]
  • [Cites] Histopathology. 2002 Jul;41(1):56-64 [12121238.001]
  • [Cites] Am J Pathol. 2002 Aug;161(2):611-8 [12163385.001]
  • [Cites] Gastric Cancer. 2004;7(1):46-53 [15052440.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):3082-90 [15131047.001]
  • [Cites] Br J Cancer. 2004 Oct 4;91(7):1342-8 [15354218.001]
  • [Cites] Gan. 1968 Jun;59(3):251-8 [5726267.001]
  • [Cites] J Histochem Cytochem. 1981 Apr;29(4):577-80 [6166661.001]
  • [Cites] Gastroenterology. 1984 Mar;86(3):461-7 [6693012.001]
  • [Cites] Clin Exp Immunol. 1984 Feb;55(2):319-32 [6365376.001]
  • [Cites] J Clin Pathol. 1985 Sep;38(9):1002-6 [2931454.001]
  • [Cites] Hum Pathol. 1986 May;17(5):482-7 [3699811.001]
  • [Cites] Cancer. 1987 Sep 1;60(5):1094-8 [3607726.001]
  • [Cites] Int J Cancer. 1988 Feb 15;41(2):184-97 [3338870.001]
  • [Cites] Hum Pathol. 1988 Aug;19(8):942-8 [3402983.001]
  • [Cites] Acta Pathol Jpn. 1990 Jul;40(7):494-504 [2220396.001]
  • [Cites] CA Cancer J Clin. 1991 Jan-Feb;41(1):19-36 [1984806.001]
  • [Cites] JAMA. 1991 Mar 13;265(10):1287-9 [1995976.001]
  • [Cites] Hum Pathol. 1991 Nov;22(11):1158-61 [1743701.001]
  • [Cites] Int J Cancer. 1992 Jan 21;50(2):202-7 [1730514.001]
  • [Cites] Cancer. 1992 Mar 1;69(5):1088-93 [1739905.001]
  • [Cites] J Am Coll Surg. 1995 May;180(5):577-82 [7749534.001]
  • (PMID = 17262083.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  • [Other-IDs] NLM/ PMC2360051
  •  go-up   go-down


2. Shen JG, Cheong JH, Hyung WJ, Kim J, Choi SH, Noh SH: Influence of a microscopic positive proximal margin in the treatment of gastric adenocarcinoma of the cardia. World J Gastroenterol; 2006 Jun 28;12(24):3883-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of a microscopic positive proximal margin in the treatment of gastric adenocarcinoma of the cardia.
  • AIM: To investigate the influence of a positive proximal margin in total gastrectomy patients with gastric adenocarcinoma of the cardia.
  • METHODS: Medical records of 191 patients with total gastrectomies for adenocarcinoma of the cardia between 1995 and 2000 were reviewed.
  • However, the difference in survival lost significance in subgroup analysis according to stage.
  • CONCLUSION: A positive margin is more of an indication of advanced disease in patients with gastric adenocarcinoma of the cardia rather than an independent prognostic factor for survival.
  • [MeSH-major] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Cardia / pathology. Gastrectomy / methods. Stomach Neoplasms / pathology. Stomach Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Surg Gynecol Obstet. 1977 Apr;144(4):563-6 [847612.001]
  • [Cites] J Gastrointest Surg. 1999 Jan-Feb;3(1):24-33 [10457320.001]
  • [Cites] Am J Surg. 1980 May;139(5):711-3 [7468923.001]
  • [Cites] Ann Surg. 1982 Dec;196(6):685-90 [7149820.001]
  • [Cites] Aust N Z J Surg. 2000 Oct;70(10):700-3 [11021482.001]
  • [Cites] Laryngoscope. 2000 Oct;110(10 Pt 1):1773-6 [11037842.001]
  • [Cites] Eur J Surg Oncol. 2000 Dec;26(8):810-4 [11087650.001]
  • [Cites] Eur J Surg Oncol. 2003 Sep;29(7):588-93 [12943624.001]
  • [Cites] Curr Probl Surg. 1973 Nov;:3-72 [4592910.001]
  • [Cites] Surg Gynecol Obstet. 1987 Sep;165(3):247-50 [3629439.001]
  • [Cites] Arch Surg. 1987 Nov;122(11):1347-51 [3675199.001]
  • [Cites] J Surg Oncol. 1989 Mar;40(3):162-9 [2465454.001]
  • [Cites] Ann Acad Med Singapore. 1989 Jan;18(1):69-71 [2712522.001]
  • [Cites] J Surg Oncol. 1989 Nov;42(3):170-4 [2811381.001]
  • [Cites] Acta Chir Scand. 1990 Feb;156(2):127-30 [2330791.001]
  • [Cites] Surgery. 1992 Apr;111(4):386-93 [1557684.001]
  • [Cites] J Surg Oncol. 1993 May;53(1):60-3 [8479199.001]
  • [Cites] Br J Surg. 1993 Nov;80(11):1418-20 [8252353.001]
  • [Cites] Am J Surg. 1995 Mar;169(3):316-9 [7879834.001]
  • [Cites] Hepatogastroenterology. 1995 Nov-Dec;42(6):873-7 [8847038.001]
  • [Cites] Eur J Cancer. 1996 Mar;32A(3):433-7 [8814687.001]
  • [Cites] Aust N Z J Surg. 1996 Nov;66(11):734-7 [8918379.001]
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Br J Surg. 1981 Feb;68(2):73-4 [7459624.001]
  • (PMID = 16804975.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4087938
  •  go-up   go-down


3. Kim MA, Lee HS, Yang HK, Kim WH: Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach. Cancer; 2005 Apr 1;103(7):1439-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic and protein expression differences between cardia carcinoma and noncardia carcinoma of the stomach.
  • BACKGROUND: Although the incidence of adenocarcinoma of the stomach has decreased over the past several decades, gastric cardia carcinoma has increased over the same period.
  • METHODS: The clinicopathologic characteristics and immunohistochemical staining results of 21 proteins were investigated in 165 patients with cardia carcinoma, including 74 patients with true cardia carcinoma and 91 patients with subcardia carcinoma, and the results were compared with the results from 564 patients with noncardia carcinoma.
  • RESULTS: In the clinicopathologic analysis, patients who had cardia carcinoma tended to have tumors with poorly differentiated histology according to the World Health Organization classification system (P = 0.012), diffuse type according to the Lauren classification system (P = 0.049), and advanced pathologic TNM stage (P < 0.001).
  • On immunohistochemical staining, loss of the p16 (P = 0.038) and smad4 (P < 0.001) tumor suppressor genes was more frequent in cardia carcinoma than in noncardia carcinoma.
  • Carcinoembryonic antigen and CD44 overexpression were more frequent in patients with cardia carcinoma (P < 0.05).
  • Conversely, patients who had cardia carcinoma exhibited less frequent expression of MUC1 (P = 0.008) and MUC5AC (P = 0.006) compared with patients who had noncardia carcinoma.
  • Epstein-Barr virus infection was more common in patients with cardia carcinoma (P < 0.001).
  • In the survival analysis, the patients with cardia carcinoma had a poorer prognosis.
  • In the multivariate analysis, tumor location in the cardia was confirmed as an independent, poor prognostic factor in patients with gastric carcinoma.
  • CONCLUSION: Cardia carcinoma and noncardia carcinoma differed in their clinicopathologic characteristics and in their alterations of gene expression, as evaluated by immunohistochemistry.
  • The current results support the hypothesis that cardia carcinoma forms a specific category of gastric carcinoma that is distinct from noncardia carcinoma.
  • [MeSH-major] Carcinoma / pathology. Cardia. Gene Expression Profiling. Stomach Neoplasms / pathology


Advertisement
4. Vissers KJ, Dinjens WN, Riegman PH, Tilanus HW, van Dekken H: Allelic imbalance on distal 7q (7q36.1-q36.3) in gastric cardia and oesophageal (Barrett's) adenocarcinoma. Anticancer Res; 2005 Mar-Apr;25(2A):913-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Allelic imbalance on distal 7q (7q36.1-q36.3) in gastric cardia and oesophageal (Barrett's) adenocarcinoma.
  • BACKGROUND: Oesophageal (Barrett's) and gastric cardia adenocarcinomas are cancers arising at and around the gastro-oesophageal junction.
  • The prognosis is poor, since detection is usually at a late stage and metastatic spread occurs early.
  • In addition, 40 gastric cardia cancers were investigated to compare the pattern of imbalance at these loci.
  • RESULTS: Overall, the number of allelic loss was higher in Barrett's cancers than in gastric cardia carcinomas (p=0.04).
  • In gastric cardia cancers, loss ranged from 12% to 27% (of informative cases), being most frequent at marker D7S3037.
  • CONCLUSION: Marker D7S483 can aid in discriminating oesophageal (Barrett's) and gastric cardia carcinomas.
  • [MeSH-major] Adenocarcinoma / genetics. Allelic Imbalance. Barrett Esophagus / genetics. Cardia / pathology. Chromosomes, Human, Pair 7 / genetics. Esophageal Neoplasms / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15868927.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


5. Wang SJ, Wu ML, Zhang LW, Guo XQ, Xu ZB, Er LM, Wang SP, Gao Y, Cong QW: [The value of endoscopic mucosal resection for dysplasia and early-stage cancer of the esophagus and gastric cardia]. Zhonghua Zhong Liu Za Zhi; 2008 Nov;30(11):853-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The value of endoscopic mucosal resection for dysplasia and early-stage cancer of the esophagus and gastric cardia].
  • OBJECTIVE: To evaluate the long-term effect and clinical value of endoscopic mucosal resection (EMR) with transparent cap for dysplasia and early-stage cancer of the esophagus and gastric cardia.
  • METHODS: From September 1996 to June 2007, 154 lesions in the esophagus or gastric cardia of 147 patients were treated using EMR with transparent cap.
  • Among the lesions, there were 69 early-stage squamous-cell carcinomas in 64 patients and 47 squamous cell precancerous lesions of the esophagus in 45 patients, with an average lesion size of (14.8 +/- 6.1) mm (range, 3-40 mm), furthermore, there were 23 early-stage adenocarcinomas in 23 patients and 15 precancerous lesions in the gastric cardia in 15 patients, with an average lesion size of (8.2 +/- 4.3) mm (rang, 5-25 mm).
  • The 5-year survival rate was 96.2% for early-stage esophageal cancer, and 100% for early cancer of the gastric cardia.
  • CONCLUSION: Endoscopic mucosal resection is suitable to treat precancerous lesions or early-stage esophageal cancers without invasion into submucosa.
  • [MeSH-major] Cardia. Esophageal Neoplasms / surgery. Esophagoscopy / methods. Precancerous Conditions / surgery. Stomach Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Female. Follow-Up Studies. Gastric Mucosa / pathology. Gastric Mucosa / surgery. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173832.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


6. Solerio D, Camandona M, Gasparri G, Casalegno PA, Raggio E, Dei Poli M: [The choice of surgical therapy in adenocarcinoma of the cardia]. Minerva Chir; 2005 Feb;60(1):17-22
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The choice of surgical therapy in adenocarcinoma of the cardia].
  • [Transliterated title] La scelta della terapia chirurgica nell'adenocarcinoma del cardias.
  • AIM: From 1996 the adenocarcinoma of the esophago-gastric junction (AEG) is divided into 3 types according to Siewert's classification.
  • METHODS: From 1990 to 2002 we have performed 111 resections for adenocarcinoma of the cardia: 25 for AEG type I (all esophago-gastric resection), 39 for type II (22 esophago-gastric resection, 17 extended total gastrectomy with esophageal resection) and 47 for type III (8 esophago-gastric resection, 39 extended total gastrectomy with esophageal resection).
  • For AEG type II any significant difference in survival is associated with surgical strategy, also in early stage (p>0.01).
  • [MeSH-major] Adenocarcinoma / surgery. Cardia. Esophageal Neoplasms / surgery. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15902049.001).
  • [ISSN] 0026-4733
  • [Journal-full-title] Minerva chirurgica
  • [ISO-abbreviation] Minerva Chir
  • [Language] ita
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


7. Guo W, Dong Z, Chen Z, Yang Z, Wen D, Kuang G, Guo Y, Shan B: Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma. Cancer Invest; 2009 May;27(4):459-65
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant CpG island hypermethylation of RASSF1A in gastric cardia adenocarcinoma.
  • In this work, the promoter methylation status of the RASSF1A in 92 gastric cardia adenocarcinoma (GCA) and corresponding normal tissues were investigated using Methylation-specific PCR (MSP) approach, immunohistochemistry method and RT-PCR were used respectively to examine the protein expression and mRNA expression of RASSF1A in tumors and corresponding normal tissues.
  • Methylation frequencies of stage III and IV tumor tissues were significantly higher than that in stage I and II tumor tissues (p <.05).
  • [MeSH-major] Adenocarcinoma / genetics. Cardia / chemistry. CpG Islands. DNA Methylation. Gene Expression Regulation, Neoplastic. Gene Silencing. Stomach Neoplasms / genetics. Tumor Suppressor Proteins / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19160099.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / CCND1 protein, human; 0 / RASSF1 protein, human; 0 / RNA, Messenger; 0 / Tumor Suppressor Proteins; 136601-57-5 / Cyclin D1
  •  go-up   go-down


8. Whitson BA, Groth SS, Li Z, Kratzke RA, Maddaus MA: Survival of patients with distal esophageal and gastric cardia tumors: a population-based analysis of gastroesophageal junction carcinomas. J Thorac Cardiovasc Surg; 2010 Jan;139(1):43-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Survival of patients with distal esophageal and gastric cardia tumors: a population-based analysis of gastroesophageal junction carcinomas.
  • OBJECTIVE: Distal esophageal tumors and gastric cardia tumors, although only physically separated by centimeters, have different staging systems and are usually treated differently.
  • We hypothesized that gastroesophageal junction adenocarcinomas (eg, gastric cardia and distal esophageal tumors) were not distinct entities and had similar survival.
  • METHODS: Using the Surveillance, Epidemiology, and End Results database (1988-2005), we identified patients with adenocarcinomas of the distal esophagus (n = 1474) and gastric cardia (n = 192).
  • RESULTS: Even after adjusting for potential confounding covariates (location, stage, race, cancer-directed surgery, and radiation therapy), we found no significant difference between distal esophageal and gastric cardia tumors with regard to overall (hazard ratio, 1.18; 95% confidence interval, 0.99-1.41) and cancer-specific (hazard ratio, 1.09; 95% confidence interval, 0.90-1.31) survival.
  • CONCLUSION: Through a large, population-based analysis of gastric cardia and distal esophageal adenocarcinomas, we found that patients with gastroesophageal junction adenocarcinomas have similar survival rates.
  • [MeSH-major] Cardia. Esophageal Neoplasms / mortality. Esophagogastric Junction. Stomach Neoplasms / mortality
  • [MeSH-minor] Adenocarcinoma / mortality. Adenocarcinoma / therapy. Aged. Cohort Studies. Female. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 The American Association for Thoracic Surgery. Published by Mosby, Inc. All rights reserved.
  • (PMID = 19660401.001).
  • [ISSN] 1097-685X
  • [Journal-full-title] The Journal of thoracic and cardiovascular surgery
  • [ISO-abbreviation] J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Vlachos K, Siafakas N, Karameris A, Athanasas G, Theodoropoulos G, Peros G, Papadopoulos J, Hakim N: Apoptosis and adenocarcinoma of the cardia: expression of p53, Bcl-2, Bcl-XL, WAF1, and fas proteins and association with characteristics of the tumors. Int Surg; 2008 May-Jun;93(3):145-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Apoptosis and adenocarcinoma of the cardia: expression of p53, Bcl-2, Bcl-XL, WAF1, and fas proteins and association with characteristics of the tumors.
  • Paraffin-embedded sections from 31 surgically resected primary cardia adenocarcinomas were examined by immunohistochemistry.
  • Fas expression was highly correlated with tumor stage (P = 0.006), degree of differentiation (P = 0.044), and the stage of the disease (P = 0.029).
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, CD95 / metabolism. Cardia / pathology. Cyclin-Dependent Kinase Inhibitor p21 / metabolism. Esophagogastric Junction / pathology. Tumor Suppressor Protein p53 / metabolism. bcl-X Protein / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18828269.001).
  • [ISSN] 0020-8868
  • [Journal-full-title] International surgery
  • [ISO-abbreviation] Int Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antigens, CD95; 0 / Biomarkers, Tumor; 0 / CDKN1A protein, human; 0 / Cyclin-Dependent Kinase Inhibitor p21; 0 / FAS protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Tumor Suppressor Protein p53; 0 / bcl-X Protein
  •  go-up   go-down


10. Wen D, Shan B, Wang S, Zhang L, Wei L, Zhou W, Peng Q: A positive family history of esophageal/gastric cardia cancer with gastric cardia adenocarcinoma is associated with a younger age at onset and more likely with another synchronous esophageal/gastric cardia cancer in a Chinese high-risk area. Eur J Med Genet; 2010 Sep-Oct;53(5):250-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A positive family history of esophageal/gastric cardia cancer with gastric cardia adenocarcinoma is associated with a younger age at onset and more likely with another synchronous esophageal/gastric cardia cancer in a Chinese high-risk area.
  • BACKGROUND: To find a genetic component in gastric cardia adenocarcinomas (GCA).
  • The difference in AO and RASPUGIC between the positive and the negative FHUGIC GCAs is significant or nearly significant in most subgroups; minimizing the possibility of a false association due to bias or confounding (e.g. significant stage-specific differences in AO between familial and sporadic GCAs observed in the subgroup of T2,3N0M0 (P = 0.000) and T2,3,4N1M0 (P = 0.03) exclude the possibility of ascertainment bias towards an earlier diagnosis in familial cases), and the association between FHUGIC and RASPUGIC is statistically significant for GCAs of younger AO (<55 yr old, RASPUGIC 3.8% vs 1.6% vs 1.1% for the positive, negative and missing FHUGIC GCAs respectively, χ2 = 6.50, P = 0.04), but not significant for the later onset GCAs (≥55 yr old, RASPUGIC 2.5%, 1.1%, 1.9% for the positive, negative and missing FHUGIC respectively, χ2 = 4.22, P = 0.12).
  • [MeSH-major] Adenocarcinoma / genetics. Asian Continental Ancestry Group. Cardia / pathology. Esophageal Neoplasms / genetics. Neoplasms, Multiple Primary / pathology. Stomach Neoplasms / genetics

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20603233.001).
  • [ISSN] 1878-0849
  • [Journal-full-title] European journal of medical genetics
  • [ISO-abbreviation] Eur J Med Genet
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


11. Wang LD, Qin YR, Fan ZM, Kwong D, Guan XY, Tsao GS, Sham J, Li JL, Feng XS: Comparative genomic hybridization: comparison between esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-incidence area for both cancers in Henan, northern China. Dis Esophagus; 2006;19(6):459-67
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparative genomic hybridization: comparison between esophageal squamous cell carcinoma and gastric cardia adenocarcinoma from a high-incidence area for both cancers in Henan, northern China.
  • In China, gastric cardia adenocarcinoma (GCA) shares very similar geographic distribution with SCC, suggesting the possibility of similar risk factors involved in SCC and GCA carcinogenesis in these areas.
  • However, the underlying genetic alterations for esophageal and gastric cardia carcinogenesis, especially for the molecular difference between SCC and GCA, are largely unknown.
  • Gains at 3q and 8p were frequently observed in TNM stage III of both SCC and GCA.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17069589.001).
  • [ISSN] 1120-8694
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


12. Chang Y, Liu B: Difference of gene expression profiles between Barrett's esophagus and cardia intestinal metaplasia by gene chip. J Huazhong Univ Sci Technolog Med Sci; 2006;26(3):311-3
Genetic Alliance. consumer health - Barrett's Esophagus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Difference of gene expression profiles between Barrett's esophagus and cardia intestinal metaplasia by gene chip.
  • The difference of gene expression profile changes in Barrett's esophagus (BE) and cardia intestinal metaplasia (CIM) epithelium was studied and the novel associated genes were screened in the early stage by cDNA microarray.
  • 141 genes with the expression more than two time were probably related to the occurrence and development of BE and the promotion or progress in adenocarcinoma.
  • [MeSH-major] Barrett Esophagus / genetics. Cardia / pathology. Gene Expression Profiling. Oligonucleotide Array Sequence Analysis. Upper Gastrointestinal Tract / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16961278.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Liu W, Hao XS, Fan Q, Li HX, Song LN, Wang SJ, Wang PZ, Jin Y, Chen Y, Guan LY, Ping YM, Meng XL, Wang R, Liu JF, Wang XL: [Cox proportional hazard model analysis of prognosis in patients with carcinoma of esophagus and gastric cardia after radical resection]. Zhonghua Zhong Liu Za Zhi; 2008 Dec;30(12):921-5
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cox proportional hazard model analysis of prognosis in patients with carcinoma of esophagus and gastric cardia after radical resection].
  • OBJECTIVE: To investigate the factors affecting the long-term survival of patients with carcinoma of esophagus and gastric cardia after curative resection.
  • METHODS: The clinical data of 906 patients with carcinoma of esophagus and gastric cardia treated by radical resection in 1996 - 2004 were analyzed retrospectively.
  • The univariate analysis showed that age, length of tumor, pathological differentiation, number of metastatic lymph nodes, depth of invasion, involvement of adjacent organs and the TNM stage influenced the prognosis significantly (P < 0.01).
  • However, multivariate analysis showed that pathologic differentiation, number of metastatic lymph nodes, involvement of adjacent organs and TNM stage were independent prognostic factors (P < 0.05).
  • CONCLUSION: The independent prognostic factors of the patients with carcinoma of esophagus and gastric cardia are pathologic differentiation, TNM stage, number of metastatic lymph nodes, and involvement of adjacent organs.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Carcinoma, Squamous Cell / pathology. Cardia. Esophageal Neoplasms / pathology. Stomach Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Esophagectomy / methods. Female. Follow-Up Studies. Gastrectomy / methods. Humans. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Proportional Hazards Models. Retrospective Studies. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173994.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


14. Ancona E, Cagol M, Epifani M, Cavallin F, Zaninotto G, Castoro C, Alfieri R, Ruol A: Surgical complications do not affect longterm survival after esophagectomy for carcinoma of the thoracic esophagus and cardia. J Am Coll Surg; 2006 Nov;203(5):661-9
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical complications do not affect longterm survival after esophagectomy for carcinoma of the thoracic esophagus and cardia.
  • The longterm prognosis for patients undergoing operation depends largely on the pathologic stage of the disease.
  • STUDY DESIGN: A retrospective analysis was performed on patients with squamous cell carcinoma and adenocarcinoma of the thoracic esophagus and esophagogastric junction, undergoing surgical resection between January 1992 and December 2002.
  • CONCLUSIONS: Surgical complications have no negative impact on survival rates, which seem to depend exclusively on the pathologic stage of the tumor.
  • [MeSH-major] Adenocarcinoma / surgery. Carcinoma, Squamous Cell / surgery. Cardia. Esophageal Neoplasms / surgery. Esophagectomy / adverse effects. Stomach Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084327.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. Guo W, Dong Z, Guo Y, Kuang G, Yang Z, Chen Z: Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma. Eur J Med Res; 2009 Sep 28;14(10):453-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of promoter hypermethylation of the CpG island of E-cadherin in gastric cardiac adenocarcinoma.
  • The aim of this study was to investigate the promoter methylation and expression of E-cadherin gene in gastric cardiac adenocarcinoma (GCA).
  • Methylation frequencies of stage III and IV tumor tissues was significantly higher than that in stage I and II tumor tissues (P = 0.01).
  • Positive immunostaining of stage III and IV tumor tissues was significantly lower than stage I and II tumor tissues (P<0.01).
  • CONCLUSIONS: High methylation status of the 5' CpG island of E-cadherin gene may be one of the mechanisms in the development of gastric cardiac adenocarcinoma.
  • [MeSH-major] Adenocarcinoma / genetics. Cadherins / genetics. Cardia. CpG Islands. DNA Methylation. Promoter Regions, Genetic. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1998 Nov;85(11):1457-9 [9823902.001]
  • [Cites] Hum Mutat. 1998;12(4):226-37 [9744472.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15339-44 [9860970.001]
  • [Cites] Oncogene. 1999 Jan 28;18(4):869-76 [10023662.001]
  • [Cites] Hum Mol Genet. 1999 Apr;8(4):607-10 [10072428.001]
  • [Cites] Lancet. 1999 Jul 31;354(9176):356-7 [10437861.001]
  • [Cites] Int J Cancer. 1999 Nov 26;83(5):620-4 [10521797.001]
  • [Cites] Cancer Res. 1998 Sep 15;58(18):4086-9 [9751616.001]
  • [Cites] J Nutr. 2000 Feb;130(2S Suppl):338S-339S [10721901.001]
  • [Cites] Nat Genet. 2000 Jul;25(3):269-77 [10888872.001]
  • [Cites] Clin Cancer Res. 2001 Sep;7(9):2765-9 [11555590.001]
  • [Cites] Science. 2001 Dec 7;294(5549):2113-5 [11739943.001]
  • [Cites] Gut. 2003 Apr;52(4):502-6 [12631658.001]
  • [Cites] Expert Rev Mol Med. 2002 Mar;4(4):1-17 [14987388.001]
  • [Cites] Adv Cancer Res. 1990;54:1-23 [2404377.001]
  • [Cites] Curr Opin Cell Biol. 1993 Oct;5(5):797-805 [8240823.001]
  • [Cites] Cancer Res. 1994 Jul 15;54(14):3845-52 [8033105.001]
  • [Cites] Br J Cancer. 1995 Feb;71(2):376-9 [7841055.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 Aug 1;92(16):7416-9 [7543680.001]
  • [Cites] Cancer Res. 1995 Nov 15;55(22):5195-9 [7585573.001]
  • [Cites] Curr Opin Cell Biol. 1995 Oct;7(5):619-27 [8573335.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Sep 3;93(18):9821-6 [8790415.001]
  • [Cites] Int J Cancer. 1997 May 2;71(3):355-9 [9139867.001]
  • [Cites] Br J Cancer. 1997;75(9):1389-96 [9155065.001]
  • [Cites] Adv Cancer Res. 1998;72:141-96 [9338076.001]
  • [Cites] Cancer Res. 1998 May 15;58(10):2063-6 [9605742.001]
  • [Cites] Am J Pathol. 1998 Aug;153(2):333-9 [9708792.001]
  • [Cites] Gastroenterology. 1998 Dec;115(6):1381-6 [9834265.001]
  • (PMID = 19748854.001).
  • [ISSN] 0949-2321
  • [Journal-full-title] European journal of medical research
  • [ISO-abbreviation] Eur. J. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cadherins; 0 / RNA, Messenger
  • [Other-IDs] NLM/ PMC3352230
  •  go-up   go-down


16. Dassen AE, Lemmens VE, van de Poll-Franse LV, Creemers GJ, Brenninkmeijer SJ, Lips DJ, Vd Wurff AA, Bosscha K, Coebergh JW: Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands. Eur J Cancer; 2010 Apr;46(6):1101-10
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in incidence, treatment and survival of gastric adenocarcinoma between 1990 and 2007: a population-based study in the Netherlands.
  • We conducted a retrospective population-based study to evaluate trends in incidence, treatment and outcome of gastric adenocarcinoma.
  • METHODS: All patients diagnosed with gastric adenocarcinoma during 1990-2007 in the Dutch Eindhoven Cancer Registry area were included (n=4,797).
  • Trend analyses were conducted for incidence, mortality, tumour and patient characteristics, treatment and crude overall survival, according to tumour location (cardia versus non-cardia).
  • The proportion of cardia tumours remained stable.
  • Stage distribution worsened over time among patients with cardia (stages I and II: 32% in 1990-1993 and 22% in 2006-2007, p=0.005) and non-cardia (stage IV: 33% in 1990-1993 and 40% in 2006-2007, p=0.0003) cancer.
  • Five-year survival worsened over time for patients with non-cardia tumours.
  • Age and stage had significant influence on survival after stratification for tumour localisation.
  • After adjustments for relevant factors (i.e. stage), the risk of death decreased since the late 90s for patients with a cardia tumour (hazard ratio 0.8, p=0.01).
  • [MeSH-major] Adenocarcinoma. Stomach Neoplasms
  • [MeSH-minor] Aged. Cardia. Female. Humans. Incidence. Male. Middle Aged. Neoplasm Staging. Netherlands / epidemiology. Retrospective Studies. Survival Analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Ltd. All rights reserved.
  • (PMID = 20219351.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] England
  •  go-up   go-down


17. Barclay JY, Morris A, Nwokolo CU: Telomerase, hTERT and splice variants in Barrett's oesophagus and oesophageal adenocarcinoma. Eur J Gastroenterol Hepatol; 2005 Feb;17(2):221-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Telomerase, hTERT and splice variants in Barrett's oesophagus and oesophageal adenocarcinoma.
  • The aim of this study was to determine the roles of human telomerase reverse transcriptase (hTERT) mRNA expression and hTERT mRNA splicing in the regulation of telomerase enzyme activity in Barrett's oesophagus and oesophageal adenocarcinoma.
  • METHODS: Paired samples from oesophageal adenocarcinoma (n=21) and adjacent macroscopically normal mucosa, and paired samples from Barrett's oesophagus (n=16) and adjacent cardia mucosa were obtained.
  • RESULTS: In oesophageal adenocarcinoma, compared to adjacent mucosa, median telomerase activity increased significantly (from 5 to 229 total product generated (tpg), P=0.0002), but median hTERT mRNA levels were not significantly different.
  • Similarly, median telomerase activity was significantly higher in oesophageal adenocarcinoma compared to Barrett's oesophagus (229 vs 20 tpg, P=0.001), but hTERT mRNA levels were not significantly different.
  • There was no significant difference in telomerase activity and hTERT mRNA levels between Barrett's oesophagus and adjacent cardia.
  • The frequency of detection of all variants increased from cardia to Barrett's oesophagus to oesophageal adenocarcinoma (P<0.05).
  • CONCLUSIONS: A major increase in telomerase activity occurs after the Barrett's oesophagus stage in oesophageal carcinogenesis.
  • [MeSH-major] Adenocarcinoma / enzymology. Barrett Esophagus / enzymology. Esophageal Neoplasms / enzymology. Gene Expression Regulation, Neoplastic. Telomerase / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15674101.001).
  • [ISSN] 0954-691X
  • [Journal-full-title] European journal of gastroenterology & hepatology
  • [ISO-abbreviation] Eur J Gastroenterol Hepatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA, Neoplasm; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


18. Lu HZ, Wu YP, Luo W, Han YL, Cai Y, Xu X, Liang J, Liu SM, Wang MR: [Correlation between aneuploidy of chromosome 17, over-expression of TP53 and TOPIIalpha, and the clinicopathological features and diagnosis of gastric adenocarcinoma]. Zhonghua Zhong Liu Za Zhi; 2009 Oct;31(10):754-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Correlation between aneuploidy of chromosome 17, over-expression of TP53 and TOPIIalpha, and the clinicopathological features and diagnosis of gastric adenocarcinoma].
  • OBJECTIVE: The purpose of this study was to investigate the markers which can be used in auxiliary diagnosis of gastric adenocarcinoma (GAC), and their correlation with their clinicopathological features.
  • METHODS: 122 surgical specimens including 99 gastric adenocarcinoma (GAC), 18 adjacent mucosa and 5 distal normal mucosa were collected, and analyzed by in situ hybridization (FISH).
  • Higher frequency of aneuploidy of cen17 was also observed in the gastric cardia than in pylorus (P < 0.05), while no correlation was found between aneuploidy of cen17 and age, sex of patients, lymph node metastasis, and clinical stage of tumors.
  • CONCLUSION: Detection of aneuploidy of cen17 as well as over-expression of TP53 and TOPIIalpha may be helpful in the diagnosis and prognostic prediction of gastric adenocarcinoma.
  • [MeSH-major] Adenocarcinoma. Aneuploidy. Antigens, Neoplasm / metabolism. Chromosomes, Human, Pair 17 / genetics. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Stomach Neoplasms. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021828.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / Tumor Suppressor Protein p53; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


19. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K: Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Hepatogastroenterology; 2008 Sep-Oct;55(86-87):1530-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug resistance-related proteins p-glycoprotein, glutathione-s-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
  • However, the clinical significance of the expression of MDR-related proteins p-glycoprotein (PGP), glutathione-s-transferases (GST-pi), topoisomerase-II (Topo-II) and lung resistance protein (LRP) in primary gastric cardiac adenocarcinoma (PGCA) remains unclear.
  • GST-pi expression status progressively increased with increasing differentiated degree (40%, 75.8% and 88.5%, P<0.05) and clinico pathologic stage (staging 1/2 vs. 3/4, 57.1% vs. 83.3%, P<0.05).
  • No significant differences with Topo-II expression was found in relation to the clinicopathologic stage (staging 1/2 vs. 3/4, 57.1% vs. 72.9%, P>0.05) and lymphatic metastasis (with vs. without metastasis, 65.0% vs. 72.4%, P>0.05).
  • Moreover, a significant difference with the expression of LRP was found in relation to the clinicopathologic stage (staging 1/2 vs. 3/4, 38% vs. 66.6%, P<0.05), and lymphatic metastasis (with vs. without metastasis, 70.0% vs. 41.4%, P<0.05).
  • [MeSH-major] Adenocarcinoma / chemistry. Cardia / chemistry. DNA Topoisomerases, Type II / analysis. Glutathione S-Transferase pi / analysis. P-Glycoprotein / analysis. Stomach Neoplasms / chemistry. Vault Ribonucleoprotein Particles / analysis

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19102336.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


20. Shi H, Lu D, Shu Y, Shi W, Lu S, Wang K: Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma. Cancer Invest; 2008 May;26(4):344-51
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of multidrug-resistance-related proteins P-glycoprotein, glutathione-S-transferases, topoisomerase-II and lung resistance protein in primary gastric cardiac adenocarcinoma.
  • However, the clinical significance of the expression of MDR-related proteins p-glycoprotein (PGP), glutathione-s-transferases (GST-pi), topoisomerase-II (Topo-II) and lung resistance protein (LRP) in primary gastric cardiac adenocarcinoma (PGCA) remains unclear.
  • GST-pi expression status progressively increased with increasing differentiated degree (40%, 75.8% and 88.5%, P < 0.05) and clinicopathologic stage (staging 1/2 vs 3/4, 57.1% vs 83.3%, P < 0.05).
  • No significant differences with Topo-II expression were found in relation to the clinicopathologic stage (staging 1/2 vs 3/4, 57.1% vs 72.9%, P > 0.05) and lymphatic metastasis (with vs. without metastasis, 65.0% vs 72.4%, P > 0.05).
  • Moreover, a significant difference with the expression of LRP was found in relation to the clinicopathologic stage (staging 1/2 vs 3/4, 38% vs 66.6%, P < 0.05), and lymphatic metastasis (with vs without metastasis, 70.0% vs 41.4%, P < 0.05).
  • [MeSH-major] Adenocarcinoma / chemistry. Cardia / chemistry. DNA Topoisomerases, Type II / analysis. Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Gene Expression Regulation, Neoplastic. Glutathione S-Transferase pi / analysis. Neoplasm Proteins / analysis. P-Glycoprotein / analysis. Stomach Neoplasms / chemistry. Vault Ribonucleoprotein Particles / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18443954.001).
  • [ISSN] 1532-4192
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; 0 / P-Glycoprotein; 0 / Vault Ribonucleoprotein Particles; 0 / major vault protein; EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 5.99.1.3 / DNA Topoisomerases, Type II
  •  go-up   go-down


21. Wijnhoven BP, Pignatelli M, Dinjens WN, Tilanus HW: Reduced p120ctn expression correlates with poor survival in patients with adenocarcinoma of the gastroesophageal junction. J Surg Oncol; 2005 Nov 1;92(2):116-23
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reduced p120ctn expression correlates with poor survival in patients with adenocarcinoma of the gastroesophageal junction.
  • Loss of normal expression of p120ctn was associated with a higher tumor grade (P < 0.0001) but not with pTNM-stage.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Adhesion Molecules / metabolism. Esophageal Neoplasms / metabolism. Esophagogastric Junction. Lymph Nodes / pathology. Phosphoproteins / metabolism. Stomach Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Barrett Esophagus / metabolism. Biomarkers, Tumor / metabolism. Cardia. Catenins. Esophagectomy. Female. Gastrectomy. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Middle Aged. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16231374.001).
  • [ISSN] 0022-4790
  • [Journal-full-title] Journal of surgical oncology
  • [ISO-abbreviation] J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Catenins; 0 / Cell Adhesion Molecules; 0 / Phosphoproteins; 0 / delta catenin
  •  go-up   go-down


22. Madani K, Zhao R, Lim HJ, Casson AG: Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study. Eur J Cardiothorac Surg; 2010 Jun;37(6):1427-32
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic value of p53 mutations in oesophageal adenocarcinoma: final results of a 15-year prospective study.
  • OBJECTIVE: This study evaluates the clinical significance of p53 mutations in oesophageal adenocarcinoma (EADC).
  • Strict clinicopathologic criteria were used to define primary EADC (Type I), excluding gastric cardia adenocarcinoma (Type II).
  • Conventional predictors of reduced OS included advanced pathological tumour-node-metastasis (pTNM) stage (P<0.0001) and number of involved lymph nodes (0, 1-3, >3; P<0.0001).
  • [MeSH-major] Adenocarcinoma / genetics. Esophageal Neoplasms / genetics. Genes, p53. Mutation

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
  • (PMID = 20227286.001).
  • [ISSN] 1873-734X
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


23. Lai KC, Chen WC, Tsai FJ, Li SY, Jeng LB: Arginine and proline alleles of the p53 gene are associated with different locations of gastric cancer. Hepatogastroenterology; 2005 May-Jun;52(63):944-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We then evaluated the patient's age, sex, smoking and alcohol consumption habits, tumor location, cell differentiation, lymph node involvement, distant metastasis and tumor stage.
  • The proline homozygote was more frequent in the patients with gastric cancer at the cardia than in those with cancer at the antral or corpus locations. (55.56% of cardia vs. 14.28% of corpus and antrum, p=0.024).
  • Also, these polymorphisms do not seem to be associated with age, sex, smoking and alcohol consumption, cell differentiation, lymph node involvement, tumor stage and distant metastasis.
  • CONCLUSIONS: The proline allele at p53 codon 72 is associated with adenocarcinoma of the gastric cardia, and the arginine allele is associated with cancer of the antral and corpus locations.
  • [MeSH-major] Alleles. Arginine / genetics. Cardia. Codon. Gastric Fundus. Genes, p53 / genetics. Polymorphism, Single Nucleotide. Proline / genetics. Stomach Neoplasms / genetics

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. (L)-PROLINE .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15966238.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Codon; 94ZLA3W45F / Arginine; 9DLQ4CIU6V / Proline
  •  go-up   go-down


24. Shi XY, Bhagwandeen B, Leong AS: CDX2 and villin are useful markers of intestinal metaplasia in the diagnosis of Barrett esophagus. Am J Clin Pathol; 2008 Apr;129(4):571-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of 38 cardia- and 9 fundic-type mucosa samples associated with BE, 13 (34%) and 0 (0%) displayed CDX2 positivity and 21 (55%) and 1 (11%) displayed villin positivity, respectively.
  • HepPar-1 was positive in 54 (57%) of 94 cases with IM and negative in the associated cardia- and fundic-type mucosa.
  • A full-thickness CK7 staining pattern was present in 90 (96%) of samples with IM and 22 (58%) and 0 (0%) of the associated cardia- and fundic-type mucosa, respectively.
  • CDX2 and villin are sensitive markers for early-stage IM and can supplement the histologic identification of this premalignant condition in the esophagus.
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adenocarcinoma / metabolism. Adenocarcinoma / surgery. Adult. Aged. Aged, 80 and over. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Esophageal Neoplasms / diagnosis. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / surgery. Female. Humans. Keratin-7 / metabolism. Male. Metaplasia. Middle Aged. Mucous Membrane / metabolism. Mucous Membrane / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18343784.001).
  • [ISSN] 0002-9173
  • [Journal-full-title] American journal of clinical pathology
  • [ISO-abbreviation] Am. J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CDX2 protein, human; 0 / Homeodomain Proteins; 0 / Keratin-7; 0 / Microfilament Proteins; 0 / villin
  •  go-up   go-down


25. Xu DK, Zhao P, Wang CF, Shao YF, Lin HW, Tian YT: [Clinicopathological characteristics and prognosis of remnant stomach cancer--report of 45 cases]. Zhonghua Zhong Liu Za Zhi; 2006 Nov;28(11):852-4
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Of these 45 patients, 28 had lesion at anastomotic site, 9 in the gastric cardia and 8 in other locations; 19 had radical resection, 16 palliative resection and 10 exploration alone except one who had an anastomosis of remnant stomach with the jejunum.
  • The histology types included: 1 un-differentiated adenocarcinoma, 36 poorly-differentiated adenocarcinoma, 7 moderately-differentiated adenocarcinoma and 1 well-differentiated adenocarcinoma.
  • The 5-year survival rate of stage I, II, III and IV was 100%, 75%, 17.8% and 0, respectively (P < 0.05).
  • Poorly-differentiated adenocarcinoma is found to be the prevalent histological type of advanced remnant stomach cancer.
  • The prognosis of remnant stomach cancer is correlated with pTNM stage and whether having been treated with complete resection or not.
  • [MeSH-major] Adenocarcinoma / pathology. Gastrectomy / methods. Gastric Stump / pathology. Stomach Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17416009.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


26. Wang X, Wu CX, Zheng Y, Wang JJ: [Time trends and characteristics of gastric cancer incidence in urban Shanghai]. Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Sep;28(9):875-80
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Based on the computerized data from 2002 to 2004, the current characteristics of urban gastric cancer incidence were analyzed regarding sex, age, stage at diagonsis, histopathologic type and location of the tumor (s).
  • About 46.1% of all the cases had detailed records of TNM stage, in which IV stage was the majority while I stage the least.
  • Adenocarcinoma was the most common type (76.8%), followed by signet ring cell carcinoma (9.4%).
  • The proportions of adenocarcinoma and tubular adenocarcinoma were higher in males than in females while signet ring cell cancer was higher in females than in males.
  • The gastric antrum cancer of females was more common than males while the gastric cardia cancer presented quite the contrary.
  • CONCLUSION: A dramatic decreasing trend during 1973 - 2004 and several current and interesting characteristics in view of gender, age, stage at diagnosis, histopathologic type and tumor location of gastric cancer in urban Shanghai were determined in this study, which might contribute to the development of control and prevention strategy for gastric cancer.
  • [MeSH-minor] Adenocarcinoma / epidemiology. Carcinoma, Signet Ring Cell / epidemiology. China / epidemiology. Female. Humans. Incidence. Male. Regression Analysis. Urban Population

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18251271.001).
  • [ISSN] 0254-6450
  • [Journal-full-title] Zhonghua liu xing bing xue za zhi = Zhonghua liuxingbingxue zazhi
  • [ISO-abbreviation] Zhonghua Liu Xing Bing Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


27. Rosivatz E, Becker KF, Kremmer E, Schott C, Blechschmidt K, Höfler H, Sarbia M: Expression and nuclear localization of Snail, an E-cadherin repressor, in adenocarcinomas of the upper gastrointestinal tract. Virchows Arch; 2006 Mar;448(3):277-87
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Subsequently, a series of 340 adenocarcinomas of the upper gastrointestinal tract, including tumours from the oesophagus (n=154), cardia (n=102) and stomach (n=84), arranged in tissue microarrays, were examined for Snail expression and were correlated to E-cadherin expression and clinico-pathological parameters.
  • No correlation was found for nuclear Snail expression and tumour grade, Lauren's classification, WHO classification, tumour stage and tumour size.
  • [MeSH-major] Adenocarcinoma / metabolism. Cell Nucleus / metabolism. Gastrointestinal Neoplasms / metabolism. Transcription Factors / metabolism. Upper Gastrointestinal Tract / metabolism

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16328348.001).
  • [ISSN] 0945-6317
  • [Journal-full-title] Virchows Archiv : an international journal of pathology
  • [ISO-abbreviation] Virchows Arch.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Cadherins; 0 / RNA, Messenger; 0 / Transcription Factors; 0 / snail family transcription factors
  •  go-up   go-down


28. Deveci MS, Deveci G: Prognostic value of p53 protein and MK-1 (a tumor-associated antigen) expression in gastric carcinoma. Gastric Cancer; 2007;10(2):112-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Also of interest is p53, a protein that has been intensively investigated in relation to particular types of tumors, patterns of metastases, tumor stage, and prognosis.
  • MK-1 expression was more frequent in cardia tumors (71%), in large (>3 cm) tumors (60%-64%), and in specimens from patients with more than five metastatic lymph nodes (69%).
  • Of these 20 patients, 15 (52%) had tubular adenocarcinoma (TA) and 5 (38%) had signet ring cell carcinoma. p53 expression was more frequent in the tumors of male patients (55% vs 27%); in poorly differentiated TAs (60% vs 47% in well-to-moderately differentiated TAs); in smaller tumors (< or = 3 cm, 72% vs 43%-50% in larger tumors); in patients with a prominent inflammatory response (61% vs 21%; P < 0.02); and in patients with lymphatic vessel invasion (77% vs 34%; P < 0.02).
  • [MeSH-major] Adenocarcinoma / metabolism. Antigens, Neoplasm / metabolism. Biomarkers, Tumor / metabolism. Cell Adhesion Molecules / metabolism. Stomach Neoplasms / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17577621.001).
  • [ISSN] 1436-3291
  • [Journal-full-title] Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
  • [ISO-abbreviation] Gastric Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Cell Adhesion Molecules; 0 / EPCAM protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


29. Mesenas S, Vu C, McStay M, Forshaw M, Doig L, Mason R, Boyle N, Meenan J: A large series, resection controlled study to assess the value of radial EUS in restaging gastroesophageal cancer following neoadjuvant chemotherapy. Dis Esophagus; 2008;21(1):37-42
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There was no difference in T and N stage accuracies between EUS and CT following neoadjuvant chemotherapy. manova showed a reduction in maximal tumor depth by > 50% at EUS to be associated with longer survival (relative risk = 0.48, P < 0.05).

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18197937.001).
  • [ISSN] 1442-2050
  • [Journal-full-title] Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus
  • [ISO-abbreviation] Dis. Esophagus
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Mehta SP, Bailey D, Davies N: Comparative outcome of oesophagogastric cancer in younger patients. Ann R Coll Surg Engl; 2010 Sep;92(6):515-8
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: The incidence of oesophageal and gastric cardia adenocarcinoma has increased rapidly over the previous two decades.
  • The following data were recorded: duration of symptoms, number of fast-track referrals, duration from GP referral to first hospital visit and stage at presentation.
  • Stage at presentation was similar between groups, but a higher proportion of patients under 55 years were offered a curative treatment plan compared to those over 55 years (P < 0.01).
  • CONCLUSIONS: Although there was a longer referral time in patients under the age of 55 years, this had no effect on disease stage at presentation.
  • [MeSH-major] Adenocarcinoma / diagnosis. Esophageal Neoplasms / diagnosis. Stomach Neoplasms / diagnosis

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2001 Jul;96(7):2005-12 [11467625.001]
  • [Cites] Am J Gastroenterol. 2002 Mar;97(3):600-3 [11922553.001]
  • [Cites] Gut. 2002 Aug;51(2):296-7 [12117899.001]
  • [Cites] Br J Cancer. 1992 Mar;65(3):417-20 [1558797.001]
  • [Cites] Cancer. 1994 Nov 1;74(9):2425-9 [7922995.001]
  • [Cites] Gut. 1997 Oct;41(4):513-7 [9391251.001]
  • [Cites] Gut. 2009 Nov;58(11):1451-9 [19651633.001]
  • [Cites] Am Surg. 2004 Nov;70(11):954-8 [15586504.001]
  • [Cites] Am J Gastroenterol. 2005 Apr;100(4):784-91 [15784019.001]
  • [Cites] Am J Gastroenterol. 2006 Oct;101(10):2187-93 [17032182.001]
  • [Cites] Surg Endosc. 2006 Nov;20(11):1725-8 [17024539.001]
  • [Cites] Scand J Gastroenterol. 2007 Jan;42(1):17-22 [17190757.001]
  • [Cites] Am J Gastroenterol. 2007 May;102(5):957-65 [17313501.001]
  • [Cites] Am J Gastroenterol. 1999 Jan;94(1):75-9 [9934734.001]
  • (PMID = 20522292.001).
  • [ISSN] 1478-7083
  • [Journal-full-title] Annals of the Royal College of Surgeons of England
  • [ISO-abbreviation] Ann R Coll Surg Engl
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC3182797
  •  go-up   go-down


31. Ihemelandu CU, DeWitty RL Jr, Leffall LD Jr, Suryanarayana MS, Frederick WA: Trends in clinicopathologic characteristics and prognostic predictors of survival outcome in black patients with gastric carcinoma: a single institution's experience. J Surg Res; 2009 Oct;156(2):325-32
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A significant increase in the incidence of cardia/fundus tumors and stage IV tumors was noted between the two periods (P<0.02, P<0.004), 8.9% versus 12% and 71.4% versus 50.8%.
  • Significant independent predictors of a shorter gastric cancer-specific survival include tumor stage IV (HR 8.4 95% CI 2.0-35.0, P<0.003), female gender (HR 2.3 95% CI 1.0-4.9, P<0.02).
  • CONCLUSION: Increased incidence of cardia/fundus tumors and stage IV disease may contribute to the sustained higher gastric cancer-specific mortality observed amongst black patients.
  • [MeSH-major] Adenocarcinoma / mortality. Adenocarcinoma / pathology. Registries. Stomach Neoplasms / mortality. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19691978.001).
  • [ISSN] 1095-8673
  • [Journal-full-title] The Journal of surgical research
  • [ISO-abbreviation] J. Surg. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


32. Schröder W, Wirths K, Gutschow C, Vallböhmer D, Bludau M, Schumacher B, Neuhaus H, Hölscher AH: Transthoracic esophagectomy after endoscopic mucosal resection in patients with early esophageal carcinoma. J Gastrointest Surg; 2009 Feb;13(2):223-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Surgical specimens were examined for pT and pN stage according to the UICC.
  • RESULTS: Three patients had a squamous cell carcinoma (SCC) and 13 patients an adenocarcinoma (AC), nine patients with a long segment Barrett's esophagus.
  • Three of 16 patients (18.8%) with a pT1sm1, pT2, and pT3 stage had nodal metastases.
  • In two patients, a second carcinoma was detected during histopathologic work-up (1x AC in the cardia and 1x SCC in the cervical esophagus).

  • MedlinePlus Health Information. consumer health - Endoscopy.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18923875.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Sadighi S, Raafat J, Mohagheghi M, Meemary F: Gastric carcinoma: 5 year experience of a single institute. Asian Pac J Cancer Prev; 2005 Apr-Jun;6(2):195-6
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor stage based on AJCC was stage 2(12.5%), stage 3(22%), stage 4(63%) and 2% unknown.
  • Most common site of involvement was cardia (43%).
  • More than 80% of patients were diagnosed in locally advanced or metastatic stage of disease and even with neoadjuvant chemotherapy and salvage surgery the outcome was poor.
  • [MeSH-major] Adenocarcinoma / therapy. Stomach Neoplasms / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16101332.001).
  • [ISSN] 1513-7368
  • [Journal-full-title] Asian Pacific journal of cancer prevention : APJCP
  • [ISO-abbreviation] Asian Pac. J. Cancer Prev.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


34. Dumot JA, Vargo JJ 2nd, Falk GW, Frey L, Lopez R, Rice TW: An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients. Gastrointest Endosc; 2009 Oct;70(4):635-44
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MAIN OUTCOME MEASUREMENTS: Histologic response was defined by the worst pathology obtained at any level of the esophagus or gastric cardia in 1 of 3 categories:.
  • Twenty-seven of 30 patients (90%) had downgrading of pathology stage after treatment.
  • During follow-up, 3 of 6 patients with complete response had recurrence of dysplasia or cancer in the gastric cardia.
  • [MeSH-major] Adenocarcinoma / therapy. Barrett Esophagus / therapy. Carcinoma, Squamous Cell / therapy. Cryosurgery / methods. Esophageal Neoplasms / therapy

  • Genetic Alliance. consumer health - Esophageal Cancer.
  • Genetic Alliance. consumer health - Barrett's Esophagus.
  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19559428.001).
  • [ISSN] 1097-6779
  • [Journal-full-title] Gastrointestinal endoscopy
  • [ISO-abbreviation] Gastrointest. Endosc.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


35. Lazăr D, Tăban S, Sporea I, Dema A, Cornianu M, Lazăr E, Goldiş A, Vernic C: Ki-67 expression in gastric cancer. Results from a prospective study with long-term follow-up. Rom J Morphol Embryol; 2010;51(4):655-61
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We noticed an increased frequency of high MI Ki-67 carcinomas in elderly patients (p=0.03) and also in the tumors developed at cardia level and those extended in the entire stomach in the moment of diagnosis (p<0.001).
  • The histological forms associated to high Ki-67 values are represented by the anaplastic carcinoma (100% of cases) and papillary adenocarcinoma (60% of cases).We observed a close correlation between the degree of tumor differentiation and the Ki-67 score (p<0.001).
  • The results of our study do not reveal any correlation between the Lauren's Classification of gastric carcinomas, the lymphovascular invasion, the depth of tumor invasion, the TNM stage and the Ki-67 score (p>0.05).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21103622.001).
  • [ISSN] 1220-0522
  • [Journal-full-title] Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie
  • [ISO-abbreviation] Rom J Morphol Embryol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Romania
  • [Chemical-registry-number] 0 / Ki-67 Antigen
  •  go-up   go-down






Advertisement